Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic and Pharmacodynamic Evaluation from an Expansion Cohort

The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic (PK) and pharmacodynamic (PD) markers with clinical outcome. In addition, a novel PD marker based on the real-time measurement of RAF...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Quintela-Fandino, Miguel, Le Tourneau, Christophe, Duran, Ignacio, Chen, Eric X., Wang, Lisa, Tsao, Ming, Bandarchi-Chamkhaleh, Bizhan, Pham, Nhu-Ann, Do, Trevor, MacLean, Martha, Nayyar, Rakesh, Tusche, Michael W., Metser, Ur, Wright, John J., Mak, Tak W., Siu, Lillian L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838726/
https://ncbi.nlm.nih.gov/pubmed/20197396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0868
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge